Aesica is a fast-growing UK company with a global footprint.
Aesica is acquired by Consort Medical plc, bringing Aesica alongside Bespak, a leading healthcare company focused on medical device technologies for drug delivery.
Aesica’s new High Capacity Manufacturing Facility at its Queenborough, UK, site is successfully validated for commercial production. With the completion of this new facility, Aesica has expanded the commercial production of a solid dose medication used in treating one of the world’s most common lifestyle diseases; Type 2 diabetes in adults.
Aesica completes the acquisition of 3 sites from UCB in Germany and Italy and expands formulated product development and manufacturing capabilities.
Aesica ranks number three in the Sunday Times Deloitte Buyout Track 100 for 2011, by increasing profit by 106% per year.
R5, Formulation Development announces significant expansion as it starts construction of a new analytical chemistry laboratory.
Aesica invests in a new high containment facility.
Aesica continues US expansion through recruitment of a Business Development Team on the East and West Coast.
Aesica acquires formulation development and clinical trial manufacturing company, R5 Pharmaceuticals, Nottingham, UK
Aesica ranks number forty-nine in the Sunday Times Deloitte Buyout Track 100 for 2010.
Aesica acquires secondary manufacturing facility from Abbott at Queenborough, Kent, UK.
Aesica opens new API pilot plant at Cramlington site.
Aesica acquires chemical manufacturing facility from MSD at Ponders End, Enfield, UK.
Aesica established as the partner of choice for global pharmaceutical companies.
Aesica completes management buyout from BASF’s Cramlington site. The deal was funded by LDC, the private equity arm of Lloyds TSB Group.
Opening of new API technical centre at Cramlington site.
BASF acquired Boots Pharmaceuticals.
Second manufacturing plant commissioned for development.
First manufacturing plant commissioned for development.
Cramlington site purchased by Boots Pharmaceuticals